469 related articles for article (PubMed ID: 17706543)
1. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
Bogoyevitch MA; Fairlie DP
Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
[TBL] [Abstract][Full Text] [Related]
2. The ATP site of protein kinases as target for drug development: from natural compounds to gleevec.
Granot Y
Isr Med Assoc J; 2002 Aug; 4(8):633-5. PubMed ID: 12183872
[No Abstract] [Full Text] [Related]
3. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
Sheinerman FB; Giraud E; Laoui A
J Mol Biol; 2005 Oct; 352(5):1134-56. PubMed ID: 16139843
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
Mol CD; Fabbro D; Hosfield DJ
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):639-48. PubMed ID: 15503866
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
6. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
Kirkland LO; McInnes C
Biochem Pharmacol; 2009 May; 77(10):1561-71. PubMed ID: 19167366
[TBL] [Abstract][Full Text] [Related]
7. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
Cox KJ; Shomin CD; Ghosh I
Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
[TBL] [Abstract][Full Text] [Related]
8. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
[TBL] [Abstract][Full Text] [Related]
9. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
Eck MJ; Manley PW
Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
[TBL] [Abstract][Full Text] [Related]
11. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
Prudent R; Cochet C
Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
[TBL] [Abstract][Full Text] [Related]
12. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase inhibitors as a therapeutic modality.
Levitzki A
Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
[TBL] [Abstract][Full Text] [Related]
14. [Progress in the design of selective ATP-competitive kinase inhibitors].
Deng XQ; Xiang ML; Jia R; Yang SY
Yao Xue Xue Bao; 2007 Dec; 42(12):1232-6. PubMed ID: 18338633
[TBL] [Abstract][Full Text] [Related]
15. Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases.
Chène P
Drug Discov Today; 2008 Jun; 13(11-12):522-9. PubMed ID: 18549979
[TBL] [Abstract][Full Text] [Related]
16. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
17. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
18. Taming the induced folding of drug-targeted kinases.
Fernández A; Bazán S; Chen J
Trends Pharmacol Sci; 2009 Feb; 30(2):66-71. PubMed ID: 19097649
[TBL] [Abstract][Full Text] [Related]
19. Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.
Duncan JS; Haystead TA; Litchfield DW
Methods Mol Biol; 2012; 795():119-34. PubMed ID: 21960219
[TBL] [Abstract][Full Text] [Related]
20. A functional approach to questions about life, death, and phosphorylation.
Bernards R
Cancer Cell; 2005 Jun; 7(6):503-4. PubMed ID: 15950899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
